Single-Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL‐12) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2016
At a glance
- Drugs NMIL 12 1 (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors Neumedicines
- 10 Jun 2017 Biomarkers information updated
- 02 Aug 2016 Planned initiation date changed from 1 Mar 2016 to 1 Nov 2016.
- 14 Jan 2016 Planned initiation date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.